|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/09/18 Mannkind Corp 10-Q 3/31/18 84:8.6M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 736K
2: EX-10.8 Material Contract HTML 30K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 28K
13: R1 Document and Entity Information HTML 45K
14: R2 Condensed Consolidated Balance Sheets HTML 113K
15: R3 Condensed Consolidated Balance Sheets HTML 43K
(Parenthetical)
16: R4 Condensed Consolidated Statements of Operations HTML 80K
17: R5 Condensed Consolidated Statements of Comprehensive HTML 36K
Loss
18: R6 Condensed Consolidated Statements of Cash Flows HTML 115K
19: R7 Description of Business and Significant Accounting HTML 339K
Policies
20: R8 Accounts Receivable HTML 45K
21: R9 Inventories HTML 44K
22: R10 Property and Equipment HTML 88K
23: R11 Accrued Expenses and Other Current Liabilities HTML 60K
24: R12 Related-Party Arrangements HTML 78K
25: R13 Borrowings HTML 133K
26: R14 Collaboration Arrangements HTML 36K
27: R15 Sale of Intellectual Property HTML 30K
28: R16 Fair Value of Financial Instruments HTML 99K
29: R17 Stock-Based Compensation Expense HTML 38K
30: R18 Commitments and Contingencies HTML 64K
31: R19 Income Taxes HTML 29K
32: R20 Restructuring Charges HTML 37K
33: R21 Subsequent Events HTML 29K
34: R22 Description of Business and Significant Accounting HTML 401K
Policies (Policies)
35: R23 Description of Business and Significant Accounting HTML 277K
Policies (Tables)
36: R24 Accounts Receivable (Tables) HTML 43K
37: R25 Inventories (Tables) HTML 44K
38: R26 Property and Equipment (Tables) HTML 88K
39: R27 Accrued Expenses and Other Current Liabilities HTML 59K
(Tables)
40: R28 Related-Party Arrangements (Tables) HTML 80K
41: R29 Borrowings (Tables) HTML 95K
42: R30 Fair Value of Financial Instruments (Tables) HTML 92K
43: R31 Stock-Based Compensation Expense (Tables) HTML 36K
44: R32 Commitments and Contingencies (Tables) HTML 49K
45: R33 Restructuring Charges (Tables) HTML 36K
46: R34 Description of Business and Significant Accounting HTML 95K
Policies - Additional Information (Detail)
47: R35 Schedule of Potentially Dilutive Common Stock HTML 43K
Equivalent Securities (Detail)
48: R36 Schedule of Cumulative Effect of Changes to HTML 51K
Condensed Consolidated Balance Sheet for Adoption
of New Revenue Guidance (Detail)
49: R37 Schedule of Adoption of New Revenue Guidance HTML 56K
Impact on Condensed Consolidated Balance sheet
(Detail)
50: R38 Schedule of Adoption of New Revenue Guidance HTML 41K
Impact on Condensed Consolidated Statement of
Operations (Detail)
51: R39 Schedule of Adoption of New Revenue Guidance HTML 51K
Impact on Condensed Consolidated Statement of Cash
Flows (Detail)
52: R40 Schedule of Accounts Receivable, Net (Detail) HTML 33K
53: R41 Accounts Receivable - Additional Information HTML 28K
(Detail)
54: R42 Components of Inventories (Detail) HTML 35K
55: R43 Inventories - Additional Information (Detail) HTML 26K
56: R44 Property and Equipment, Net (Detail) HTML 59K
57: R45 Depreciation Expense Related to Property and HTML 27K
Equipment (Detail)
58: R46 Property and Equipment - Additional Information HTML 37K
(Detail)
59: R47 Accrued Expenses and Other Current Liabilities HTML 47K
(Detail)
60: R48 Accrued Expenses and Other Current Liabilities - HTML 29K
Additional Information (Detail)
61: R49 Schedule of Related Party Debt (Detail) HTML 37K
62: R50 Related-Party Arrangements - Additional HTML 130K
Information (Detail)
63: R51 Schedule of Interest Expense on Note Payable to HTML 26K
Related Party (Detail)
64: R52 Schedule of Amortization of Premium and Accretion HTML 32K
of Debt Issuance Costs Related to Related Party
Notes (Detail)
65: R53 Summary of Borrowings (Detail) HTML 49K
66: R54 Borrowings - Additional Information (Detail) HTML 248K
67: R55 Accretion of Debt Issuance Cost and Debt Discount HTML 30K
(Detail)
68: R56 Schedule of Amortization of Premium and Accretion HTML 32K
of Debt Issuance Costs (Detail)
69: R57 Collaboration Arrangements - Additional HTML 43K
Information (Detail)
70: R58 Sale of Intellectual Property - Additional HTML 31K
Information (Detail)
71: R59 Fair Value of Financial Instruments - Additional HTML 52K
Information (Detail)
72: R60 Fair Value of Financial Instruments (Detail) HTML 49K
73: R61 Stock Based Compensation Expense Recognized in HTML 27K
Accompanying Consolidated Statements of Operations
(Detail)
74: R62 Stock-Based Compensation - Additional Information HTML 60K
(Detail)
75: R63 Commitments and Contingencies - Additional HTML 96K
Information (Detail)
76: R64 Annual Purchase Requirements under Contract HTML 35K
(Detail)
77: R65 Schedule of Future Minimum Lease Payments (Detail) HTML 42K
78: R66 Income Taxes -Additional Information (Detail) HTML 31K
79: R67 Restructuring Charges - Additional information HTML 30K
(Detail)
80: R68 Reconciliation of Beginning and Ending Liability HTML 30K
Balances for Restructuring Charges (Detail)
81: R69 Subsequent Events - Additional Information HTML 53K
(Detail)
83: XML IDEA XML File -- Filing Summary XML 153K
82: EXCEL IDEA Workbook of Financial Reports XLSX 99K
7: EX-101.INS XBRL Instance -- mnkd-20180331 XML 2.42M
9: EX-101.CAL XBRL Calculations -- mnkd-20180331_cal XML 164K
10: EX-101.DEF XBRL Definitions -- mnkd-20180331_def XML 635K
11: EX-101.LAB XBRL Labels -- mnkd-20180331_lab XML 1.21M
12: EX-101.PRE XBRL Presentations -- mnkd-20180331_pre XML 1.00M
8: EX-101.SCH XBRL Schema -- mnkd-20180331 XSD 211K
84: ZIP XBRL Zipped Folder -- 0001564590-18-012419-xbrl Zip 185K
Exhibit 10.8
***Text Omitted and Filed Separately
with the Securities and Exchange Commission.
Confidential Treatment Requested
Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2
THIRD AMENDMENT TO SUPPLY AGREEMENT
This third amendment (“Third Amendment”) to the Supply Agreement by and between MannKind Corporation (“MannKind”) and Amphastar Pharmaceuticals, Inc. (“Amphastar”), originally dated July 31, 2014 and as previously amended on October 31, 2014 and November 9, 2016 (collectively, the “Agreement”), is hereby made as of the 11th day of April, 2018, by and between MannKind on the one hand, and on the other hand, Amphastar.
RECITALS:
WHEREAS, MannKind and Amphastar entered into the Agreement pursuant to which Amphastar is to manufacture and supply the Product to MannKind, and MannKind is to purchase certain minimum quantities of the Product;
WHEREAS, any distribution or sales by MannKind of the Product or the MannKind Product made using the Product shall be limited to the Territory; and
WHEREAS MannKind and Amphastar have determined it to be mutually beneficial to amend the Agreement as set forth herein.
NOW, THEREFORE, for good and valuable consideration, MannKind and Amphastar, hereby agree to amend the Agreement as follows:
1.Definitions. Unless otherwise defined herein, each of the capitalized terms used in this Third Amendment shall have the definition and meaning ascribed to it in the Agreement.
2.Amendments to the Agreement.
2.1Section 1.4 of the Agreement is amended and replaced in its entirety with the following:
“‘Excluded Countries’ means […***…]”
3.Final Agreement.
From and after the execution of this Third Amendment, all references in the Agreement (or in the Third Amendment) to “this Agreement,” “hereof,” “herein,” “hereto,” and similar words or phrases shall mean and refer to the Agreement as amended by this Third Amendment. The Agreement as amended by this Third Amendment constitutes the entire agreement by and between the Parties as to the subject matter hereof. Except as expressly modified by this Third Amendment, all other terms and conditions of the Agreement shall remain in full force and effect.
IN WITNESS WHEREOF, each of MannKind and Amphastar has caused this Third Amendment to be executed by their duly authorized officers.
MannKind Corporation
By:/s/ Michael Castagna _____________
Name:Michael Castagna
Title:Chief Executive Officer
Amphastar Pharmaceuticals, Inc.
By:/s/ Jason Shandell _______________
Name:Jason Shandell
Title:President
2
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/9/18 | 8-K | ||
| For Period end: | 3/31/18 | |||
| 11/9/16 | 10-Q, 8-K | |||
| 10/31/14 | 4 | |||
| 7/31/14 | 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/24 Mannkind Corp. 10-K 12/31/23 123:18M Donnelley … Solutions/FA 2/23/23 Mannkind Corp. 10-K 12/31/22 135:24M ActiveDisclosure/FA 2/24/22 Mannkind Corp. 10-K 12/31/21 108:17M ActiveDisclosure/FA 2/25/21 Mannkind Corp. 10-K 12/31/20 107:15M ActiveDisclosure/FA |